Updated timeline for conversion of NeuroVive’s BTUs into

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of NeuroVive’s BTUs into shares and warrants. THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. The last day of trading in BTUs will be 24 May 2016, and the first day of trading in new shares and warrants (series 2016/2017:1 and series 2016/2017:2) will be 26 May 2016. The conversion of BTUs in the Euroclear system will be effected on 26 May 2016, and the new shares and warrants will appear in the relevant VP accounts on 30 May 2016.  After the completion of the new issue, NeuroVive’s share capital amounts to SEK 2,472,932.25. The total number of shares after registration is 49,458,645. Advisors Stockholm Corporate Finance AB acted as financial advisor and Advokatfirman Lindahl KB acted as legal advisor to the company in connection with the new issue. Aqurat Fondkommission AB acted as issuing institution in connection with the new issue and Laika Consulting was responsible for IR and marketing. About NeuroVive NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden. For investor relations and media questions, please contact: Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com, www.neurovive.com  (http://www.neurovive.com/)NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 23 May 2016, at 17.15 CET. IMPORTANT INFORMATION Publication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and the people in jurisdictions where this press release has been made public or distributed should inform themselves and follow such legal restrictions. This press release does not contain and does not constitute or form part of an invitation to acquire or subscribe or a solicitation of any offer to buy or subscribe for shares or other securities in NeuroVive. This press release may not be published or distributed, directly or indirectly, in or into the US, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or in any other jurisdiction where such distribution would be prohibited by applicable law. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 or applicable laws of other jurisdictions. NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find Real-Time quotes and market information for the company at  www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/N E VPF/quot)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Appian Partners with Children's National to Elevate Healthcare

Updated Category News Views 87

Appian Teams Up with Children’s National Hospital Appian, known for its cutting-edge software solutions, is excited to share its new collaboration with Children’s National Hospital, one of the top names in pediatric healthcare. This partnership aims to raise awareness and gather essential resources for children's health. Appian is dedicated to enhancing the healthcare...

Continue Reading
Deutsche Bank Predicts ECB Rate Cuts Amid Falling Inflation

Updated Category News Views 101

Deutsche Bank dropped a prediction back in late 2023 that the European Central Bank (ECB) was gearing up for interest rate cuts this October. Traders perked up when they caught wind of unexpected dips in inflation figures from the eurozone noted earlier that September. Why the Cut? Inflation Insights Unpacked Analysts at Deutsche Bank, led by chief economist Mark Wall,...

Continue Reading
Vipshop's Financial Performance Analysis for 2024 Revealed

Updated Category News Views 390

Vipshop's Financial Insights for 2024 Vipshop Holdings Limited (NYSE: VIPS), a prominent online discount retailer in the Chinese market, has recently shared its unaudited financial results for the quarter and full year that concluded on December 31, 2024. Despite encountering challenges over the previous year, Vipshop's performance indicates resilience and potential...

Continue Reading
Boston University and Infocap Partner for Digital Transformation

Updated Category News Views 207

Boston University's Digital Business Institute Partners with Infocap BOSTON--The Digital Business Institute (DBI) at Boston University Questrom School of Business and Infocap AI Corp, a leader in human-centric automation, have announced a strategic partnership aimed at revolutionizing digital transformation across the banking sector. This collaboration is particularly...

Continue Reading
Disclosure and Investment Position Overview for Keywords Studios

Updated Category News Views 116

Understanding Disclosure and Investment Positions In the complex world of stock market investments, transparency is crucial. This is especially true for organizations involved with Keywords Studios PLC, a leading player in the gaming services sector. This article seeks to shed light on the recent disclosures and key investments associated with this prominent company. Key...

Continue Reading